2013 Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012

AMAG Pharmaceuticals Announces Presentation at Jefferies 2013 Global Healthcare Conference in London

WALTHAM, Mass., Nov. 15, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that Frank Thomas, AMAG's chief operating officer, will present at the Jefferies 2013 Global Healthcare Conference in London on Thursday, November 21, 2013 ... More > 

AMAG Pharmaceuticals Appoints Robert F. Kaper, M.D. as Senior Vice President of Medical and Scientific Affairs

WALTHAM, Mass., Oct. 29, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Robert F. Kaper, M.D. to the role of senior vice president of medical and scientific affairs (recently vacated). Dr. Kaper brings to AMAG more than 20 years of healthcare exp... More > 

AMAG Reports Third Quarter and Nine Month 2013 Financial Results

Another Quarter of Record U.S. Feraheme Sales  Company Achieves Cash-flow Positive Quarter Strong Performance Leads to Updated Full-year 2013 Financial Guidance Conference call scheduled for 8:00 a.m. EDT today WALTHAM, Mass., Oct. 23, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals,... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on October 23, 2013 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended September 30, 2013

WALTHAM, Mass., Oct. 17, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter and nine months ended September 30, 2013 before the U.S. financial markets open on Wednesday, October 23, 2013. The annou... More > 

AMAG Pharmaceuticals Receives Notice of 3-month Extension of the PDUFA Action Date for the Supplemental New Drug Application for Feraheme(R) for the Broader IDA Indication

Conference Call Scheduled for 8:00 a.m. on Thursday, October 17th WALTHAM, Mass., Oct. 16, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has extended its review of a supplemental new drug application (sNDA) for Fer... More > 

Ferumoxytol Abstract Recognized as a Presidential Poster Recipient at American College of Gastroenterology Annual Scientific Meeting

WALTHAM, Mass., Oct. 14, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced that a poster being presented today at the 2013 American College of Gastroenterology's (ACG) annual scientific meeting was recognized as a Presidential Poster Award recipient. The abstract reported o... More > 

AMAG Pharmaceuticals Announces Appointment of Barbara Deptula to Board of Directors

LEXINGTON, Mass., Sept. 9, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that Barbara Deptula, former executive vice president and chief corporate development officer of Shire plc, has been elected to AMAG's Board of Directors, effective September 6, 2013. Ms.... More > 

AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will participate in two upcoming investor conferences. The sessions will include a brief company presentation followed by a question and a... More > 

AMAG Pharmaceuticals Announces Issuance of New U.S. Patent for Ferumoxytol

LEXINGTON, Mass., Aug. 7, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the United States Patent and Trademark Office (USPTO) has issued a new U.S. patent to AMAG for ferumoxytol, U.S. Patent No. 8,501,158, Polyol and Polyether Iron Oxide Complexes as Pharmac... More > 

AMAG Announces Second Quarter and Six Month 2013 Financial Results

Record Provider Demand Drives 29% Increase in U.S. Net Feraheme Revenues Company Updates Financial Guidance; Increases Revenue Projections for 2013 Conference call scheduled for 8:00 a.m. EDT today LEXINGTON, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on August 1, 2013 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended June 30, 2013

LEXINGTON, Mass., July 30, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter ended June 30, 2013 before the U.S. financial markets open on Thursday, August 1, 2013. The announcement will be follow... More > 

AMAG Pharmaceuticals Appoints Carol Satler, M.D., Ph.D. as Senior Vice President of Medical and Scientific Affairs

LEXINGTON, Mass., July 23, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Carol Satler, M.D, Ph.D. as senior vice president of medical and scientific affairs. Dr. Satler brings to AMAG more than 25 years of healthcare experience, including 15 yea... More > 

AMAG Pharmaceuticals Appoints Amit Verma as Vice President of Marketing

LEXINGTON, Mass., July 3, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Amit Verma as vice president of marketing. Mr. Verma comes to AMAG with extensive marketing and sales experience, most recently with the oncology division of Sanofi where he... More > 

New Campaign Wants Patients to Know "Iron Matters"

Nationwide Survey Underscores Need for Greater Understanding of the Importance of Iron LEXINGTON, Mass., June 24, 2013 (GLOBE NEWSWIRE) -- In response to a recent national survey finding that three-quarters of Americans don't fully understand the role that iron plays in the body,1 AMAG Pharmaceutic... More > 

AMAG Pharmaceuticals Appoints Steven Caffe, M.D. as Chief Development and Regulatory Officer

LEXINGTON, Mass., June 24, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Steven Caffé, M.D. as senior vice president and chief development and regulatory officer. Dr. Caffé brings 20 years of experience in global biopharmaceuticals development a... More > 

AMAG Pharmaceuticals Obtains US Commercial Rights to MuGard(TM) A Prescription Oral Rinse to Manage Oral Mucositis

Expands AMAG's Product Offerings for Hematology/Oncology Patients and Clinics LEXINGTON, Mass., June 10, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today that it has licensed the US commercial rights to MuGard™, a marketed product for the management of oral mucositi... More > 

AMAG Pharmaceuticals Announces Submission of a Type II Variation for Rienso Label Expansion in Europe to Include All Adult Iron Deficiency Anemia Patients Who Cannot Take Oral Iron

LEXINGTON, Mass., June 7, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that its European commercial partner, Takeda Pharmaceutical Company Limited, has submitted a type-II variation to the European Medicines Agency (EMA) for Rienso® (ferumoxytol). The submission ... More > 

AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

LEXINGTON, Mass., June 3, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Jefferies 2013 Global Healthcare Conference on Wednesday, June 5, 2013 at 9:00 am ET in New York. Also, Frank Thomas, A... More > 

Ferumoxytol Treatment Produced Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Gastrointestinal Disease Who Had Failed or Could Not Tolerate Oral Iron Therapy

Sub-Group Analysis of a Phase III Trial Being Presented Today in a Poster Session at Digestive Disease Week LEXINGTON, Mass., May 21, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced that a new sub-group analysis from IDA-301, a phase III, randomized, placebo-controlled c... More > 

Ferumoxytol Results in Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed or Could Not Tolerate Oral Iron Therapy

Sub-Group Analysis of a Phase III, Randomized, Placebo-Controlled Trial Being Presented Today in a Poster Session at the American College of Obstetrics and Gynecology Annual Meeting LEXINGTON, Mass., May 6, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that a new... More > 

AMAG Pharmaceuticals to Present at the Needham Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 26, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will present at the Needham Healthcare Conference on Wednesday, May 1, 2013 at 12:50 p.m. Eastern time. The pr... More > 

AMAG Announces First Quarter 2013 Financial Results

Total revenue increased 16%, operating expenses decreased 24%, resulting in a 69% reduction in net loss Conference call scheduled for 4:30 EDT today LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 23, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharm... More > 

AMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 19, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2013 after the U.S. financial markets close on Tuesday, April 23, 2013. The... More > 

AMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause

AMAG to Host a Conference Call at 8:00 a.m. EDT Today LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 15, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced positive preliminary data from the IDA-303 study. IDA-303 is a single arm, open-label extension s... More > 

AMAG Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Feraheme Label Expansion to Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 6, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the United States Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for Feraheme® (ferumoxy... More > 

AMAG Announces Fourth Quarter and Year End 2012 Financial Results

Increased total revenue by 39% over 2011 Reduced operating expenses by 32% over 2011 Reduced net loss by 79% over 2011 LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 1, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical ... More > 

AMAG Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 21, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, February 26, 2013 at ... More > 

AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 7, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will participate in the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at 2:00 ... More > 

AMAG Pharmaceuticals Provides Business Update Announces Preliminary 2012 Financial Results and 2013 Financial Guidance

~ Submits sNDA for expanded indication for Feraheme® (ferumoxytol) ~ ~ Achieves 14% growth in fourth quarter 2012 U.S. Feraheme product revenues, compared to fourth quarter of 2011 ~ ~ Ends 2012 with approximately $227 million in cash and ... More > 

AMAG Pharmaceuticals Appoints Greg Madison as Chief Commercial Officer

LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 2, 2013-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the appointment of Greg Madison as executive vice president and chief commercial officer. Mr. Madison brings a wealth of hands-on commercial experience and exte... More >